BioMarin Pharmaceuticals
BMRN
542 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 193 increasing their positions, 194 reducing their positions, and 70 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
7% more capital invested
Capital invested by funds: $13.7B → $14.7B (+$989M)
0.02% more ownership
Funds ownership: 96.75% → 96.76% (+0.02%)
1% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 194
7% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 70
10% less call options, than puts
Call options by funds: $85.1M | Put options by funds: $94.2M
3% less funds holding
Funds holding: 560 → 542 (-18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$159M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$104M |
| 3 |
SIG
Senator Investment Group
New York
|
+$67.7M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$55.9M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$52.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$355M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.8M |
| 3 |
ClearBridge Investments
New York
|
-$78.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$74.6M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
-$60.4M |
BMRN Hedge Fund Activity: Q2 2022 in Review
542 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2022, worth a combined $14.7B — up 7.2% from $13.7B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of BMRN and 65 opened new positions — a net loss of 5 holders — while 194 trimmed existing stakes and 193 added.
The largest buyer was Barclays, adding an estimated $159M. The largest seller was Capital Research Global Investors, cutting an estimated $355M.
- 542 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2022, down from 560 in Q1 2022.
- Funds reported $14.7B of BioMarin Pharmaceuticals stock for Q2 2022, up 7.2% quarter-over-quarter.
- 65 funds opened new BioMarin Pharmaceuticals positions in Q2 2022 and 70 closed out, a net change of -5 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2022 was Barclays, an estimated $159M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2022 was Capital Research Global Investors, an estimated $355M sold.
Based on aggregated 13F filings for Q2 2022.